BiotechTube

Placebo + AMG 167

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Osteopenia

Conditions

Osteopenia

Trial Timeline

Jun 1, 2010 → Feb 1, 2012

NCT ID
NCT01101048

About Placebo + AMG 167

Placebo + AMG 167 is a phase 1 stage product being developed by Amgen for Osteopenia. The current trial status is completed. This product is registered under clinical trial identifier NCT01101048. Target conditions include Osteopenia.

What happened to similar drugs?

5 of 10 similar drugs in Osteopenia were approved

Approved (5) Terminated (0) Active (5)
✅Teriparatide + Zoledronic AcidEli LillyApproved
✅alendronate sodiumMerckApproved
🔄zoledronic acidNovartisPhase 3
✅zoledronic acid vs pamidronateNovartisApproved
🔄Zoledronic Acid + PlaceboNovartisPhase 3
✅Placebo + ibandronate [Bonviva/Boniva]RocheApproved
🔄ibandronate [Bonviva/Boniva] + PlaceboRochePhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01101048Phase 1Completed

Competing Products

18 competing products in Osteopenia

See all competitors
ProductCompanyStageHype Score
Teriparatide + Zoledronic AcidEli LillyApproved
43
alendronate sodiumMerckApproved
43
zoledronic acidNovartisPhase 3
40
zoledronic acid vs pamidronateNovartisApproved
43
Zoledronic Acid + PlaceboNovartisPhase 3
40
BPS804 20mg/Kg + Placebo to 20mg/Kg BPS804NovartisPhase 2
35
Placebo + ibandronate [Bonviva/Boniva]RocheApproved
43
ibandronate [Bonviva/Boniva] + PlaceboRochePhase 3
40
Romosozumab + PlaceboAmgenPhase 1
29
AMG 167 + PlaceboAmgenPhase 1
29
Romosozumab + PlaceboAmgenPhase 1
29
DenosumabAmgenPhase 3
40
Romosozumab + PlaceboAmgenPhase 1
29
Dasatinib 100 Mg Oral TabletNovo NordiskPhase 2
39
RN564PfizerPhase 1
29
risedronate + alendronateSanofiPhase 1
29
Menostar (Estradiol, BAY86-5435) + RaloxifeneBayerPhase 3
37
tibolone + raloxifenOrganonApproved
37